282 related articles for article (PubMed ID: 36637815)
1. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
[TBL] [Abstract][Full Text] [Related]
2. Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
Hayford TB
JAMA Health Forum; 2024 May; 5(5):e241188. PubMed ID: 38787543
[TBL] [Abstract][Full Text] [Related]
3. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
Rome BN; Feldman WB; Desai RJ; Kesselheim AS
JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
[TBL] [Abstract][Full Text] [Related]
4. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
Hernandez I; San-Juan-Rodriguez A; Good CB; Gellad WF
JAMA; 2020 Mar; 323(9):854-862. PubMed ID: 32125403
[TBL] [Abstract][Full Text] [Related]
5. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
Wineinger NE; Zhang Y; Topol EJ
JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
[TBL] [Abstract][Full Text] [Related]
6. Inflationary Rebates For Generic Drugs Sold Through Medicaid Saved Billions During 2017-20.
Rome BN; Patel AN; Kesselheim AS
Health Aff (Millwood); 2023 Jun; 42(6):770-778. PubMed ID: 37276474
[TBL] [Abstract][Full Text] [Related]
7. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
Raimond VC; Feldman WB; Rome BN; Kesselheim AS
Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
[TBL] [Abstract][Full Text] [Related]
8. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
[TBL] [Abstract][Full Text] [Related]
9. Medicaid Spending on Antiretrovirals From 2007 Through 2019.
Walsh BS; Kesselheim AS; Rome BN
Clin Infect Dis; 2023 Mar; 76(5):833-841. PubMed ID: 36268585
[TBL] [Abstract][Full Text] [Related]
10. Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020.
Desai A; Scheckel C; Jensen CJ; Orme J; Williams C; Shah N; Leventakos K; Adjei AA
JAMA Netw Open; 2022 Jan; 5(1):e2144923. PubMed ID: 35076701
[TBL] [Abstract][Full Text] [Related]
11. The Medicaid Rebate: Changes in Oncology Drug Prices After the Affordable Care Act.
Bonakdar Tehrani A; Carroll NV
Appl Health Econ Health Policy; 2017 Aug; 15(4):513-520. PubMed ID: 28224469
[TBL] [Abstract][Full Text] [Related]
12. Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare.
Egilman AC; Rome BN; Kesselheim AS
JAMA; 2023 Apr; 329(15):1283-1289. PubMed ID: 37071095
[TBL] [Abstract][Full Text] [Related]
13. Estimating Rebates and Other Discounts Received by Medicare Part D.
Feldman WB; Rome BN; Raimond VC; Gagne JJ; Kesselheim AS
JAMA Health Forum; 2021 Jun; 2(6):e210626. PubMed ID: 36218748
[TBL] [Abstract][Full Text] [Related]
14. Projected spending for brand-name drugs in English primary care given US prices: a cross-sectional study.
Liu M; MacKenna B; Feldman WB; Walker AJ; Avorn J; Kesselheim AS; Goldacre B
J R Soc Med; 2020 Sep; 113(9):350-359. PubMed ID: 32910868
[TBL] [Abstract][Full Text] [Related]
15. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Commercial and Mandatory Discounts in the Gross-to-Net Bubble for the Top Insulin Products From 2012 to 2019.
Dickson SR; Gabriel N; Gellad WF; Hernandez I
JAMA Netw Open; 2023 Jun; 6(6):e2318145. PubMed ID: 37314806
[TBL] [Abstract][Full Text] [Related]
17. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
Dickson S; Reynolds I
JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
[TBL] [Abstract][Full Text] [Related]
18. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
20. Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing Boards.
Bendicksen L; Rome BN; Avorn J; Kesselheim AS
Milbank Q; 2021 Dec; 99(4):1162-1197. PubMed ID: 34375015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
